CAJ | 학술논문

目的研究辅助性肝动脉化疗栓塞(TACE)对原发性肝癌切除术后患者预后的影响,为临床评估术后合理选择辅助性TACE提供参考.方法回顾性分析福建医科大学附属泉州第一医院2002-2008年311例原发性肝癌患者的临床资料.利用COX回归模型逐步分析,Kaplan-Meier法分析辅助性TACE对肿瘤直径≤5 cm高危组(76例)、低危组(91例)以及肿瘤直径＞5 cm高危组(65例)、低危组(78例)患者预后的影响.低危组定义为肿瘤单发且无血管侵犯;高危组定义为肿瘤多发和(或)血管侵犯.结果在肿瘤直径＞5 cm高危组,术后行辅助性TACE者总生存期高于术后未行辅助性TACE者(P＜0.05).其他亚组术后是否行辅助性TACE对总生存期无明显影响(P＞0.05).结论辅助性TACE对于肿瘤直径＞5 cm的高危组肝癌术后患者是有受益的.
목적 연구보조성간동맥화료전새(TACE)대원발성간암절제술후환자예후적영향,위림상평고술후합리선택보조성TACE제공삼고.방법 회고성분석복건의과대학부속천주제일의원2002-2008년311례원발성간암환자적림상자료.이용COX회귀모형축보분석,Kaplan-Meier법분석보조성TACE대종류직경≤5 cm고위조(76례)、저위조(91례)이급종류직경＞5 cm고위조(65례)、저위조(78례)환자예후적영향.저위조정의위종류단발차무혈관침범;고위조정의위종류다발화(혹)혈관침범.결과 재종류직경＞5 cm고위조,술후행보조성TACE자총생존기고우술후미행보조성TACE자(P＜0.05).기타아조술후시부행보조성TACE대총생존기무명현영향(P＞0.05).결론 보조성TACE대우종류직경＞5 cm적고위조간암술후환자시유수익적.
Objective To study the effect of postoperative adjuvant transarterial chemoembolization (TACE) on prognosis of patients after radical resection of primary hepatocellular carcinoma.Methods A retrospective analysis was conducted on 311 patients with primary hepatocellular carcinoma treated from 2002 to 2008 in Quanzhou First Hospital affiliated to the Fujian Medical University.Utilizing the COX regression model and the Kaplan-Meier analysis,the effects of adjuvant TACE on prognosis of both the high risk group (n =76) and the low risk group (n =91) with tumor ≤5 cm,as well as both the high risk group (n =65) and the low risk group (n =78) with tumor ＞ 5 cm were determined.The low risk group was defined as patients with a single tumor and without vascular invasion,while the high risk group was defined as patients with multiple tumors or with vascular invasion.Results The postoperative overall survival rate of the high risk group who underwent postoperative adjuvant TACE with tumor ＞ 5 cm was higher than that of the high risk group who did not undergo postoperative adjuvant TACE (P ＜ 0.05).However,whether or not postoperative adjuvant TACE was given had no effect on prognosis in the other subgroups of patients (P ＞ 0.05).Conclusion Postoperative adjuvant TACE was beneficial to the high risk group of patients with tumor ＞ 5 cm after radical resection of primary hepatocellular carcinoma.